Med2Date — Clinical Guidelines
Home Immunology Immunoglobulins

Immunoglobulins

Last updated 31 May 2026 · Immunology clinical guideline

📋 Key Information Summary

📋
  • Immunoglobulins (antibodies) are Y-shaped glycoproteins composed of two heavy chains and two light chains linked by disulphide bonds.
  • Five immunoglobulin classes exist: IgG (most abundant, crosses placenta), IgA (mucosal defence), IgM (first responder), IgD (B-cell receptor), IgE (allergy and parasitic defence).
  • IgG has four subclasses (IgG1–4); IgA has two (IgA1, IgA2); subclass deficiencies may cause clinical immunodeficiency despite normal total Ig levels.
  • Effector functions include neutralisation, opsonisation, complement activation (classical pathway), antibody-dependent cellular cytotoxicity (ADCC), and mast-cell degranulation.
  • Intravenous immunoglobulin (IVIg) is indicated for primary immunodeficiency, immune thrombocytopenia (ITP), Kawasaki disease, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and specific autoimmune conditions.
  • Subcutaneous immunoglobulin (SCIg) offers equivalent efficacy to IVIg for antibody-replacement therapy with superior steady-state IgG levels and fewer systemic adverse effects.
  • IVIg dose varies by indication: 0.4 g/kg/month for replacement; 1–2 g/kg (often over 2–5 days) for immunomodulation.
  • Common adverse effects include headache, flushing, myalgia, and rigors; serious risks include anaphylaxis in IgA-deficient patients with anti-IgA antibodies, thromboembolic events, and aseptic meningitis.
  • Australian blood-plasma supply is managed by Lifeblood (Australian Red Cross) and CSL Behring; IVIg products available in Australia include Intragam P, Privigen, Flebogamma, and Kiovig.
  • In Australia, IVIg and SCIg are funded under the National Blood Agreement; prescribing requires compliance with the National Immunoglobulin Governance Programme (NIGP) and State/Territory Blood Management Committees.
  • Aboriginal and Torres Strait Islander peoples have higher rates of infections that may benefit from immunoglobulin therapy but face barriers to specialist referral, plasma-donation infrastructure, and regular infusion access.
  • Monoclonal antibodies (therapeutic mAbs) are immunoglobulin-derived biologics and are distinct from pooled immunoglobulin products; they target specific antigens (e.g., rituximab targets CD20).

Introduction & Australian Context

Immunoglobulins (antibodies) are glycoproteins produced by terminally differentiated B lymphocytes (plasma cells) that specifically bind antigens, thereby mediating the effector functions of humoral immunity. Each immunoglobulin molecule comprises two identical heavy chains and two identical light chains arranged in a Y-shaped quaternary structure linked by inter-chain disulphide bonds.

In Australia, immunoglobulin products are classified as biological medicines under the oversight of the Therapeutic Goods Administration (TGA). The supply of plasma-derived and recombinant immunoglobulin products is governed by the National Blood Agreement between the Commonwealth, State, and Territory governments. Australian Red Cross Lifeblood collects approximately 750 000 plasma donations annually, yet domestic demand for immunoglobulin continues to grow at 5–8 % per year, driven by expanding indications for immunomodulation.

The National Immunoglobulin Governance Programme (NIGP) provides a framework for evidence-based, appropriate use of immunoglobulin products. Prescribers must comply with NIGP criteria and obtain approval through their State or Territory Blood Management Committee before initiating immunoglobulin therapy, except in life-threatening emergencies.

This guideline provides a comprehensive overview of immunoglobulin structure, classification, effector functions, and clinical applications relevant to Australian primary care and specialist practice.

Immunoglobulins clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge — Immunoglobulins: pathophysiology, clinical clues, diagnosis, imaging, and management.
Immunoglobulins infographic, full size

Structure — Heavy & Light Chains

Basic Immunoglobulin Architecture

Every immunoglobulin molecule is a heterotetramer consisting of:

  • Two identical heavy (H) chains — approximately 50–70 kDa each. The heavy-chain constant region determines the immunoglobulin class (isotype): γ for IgG, α for IgA, μ for IgM, δ for IgD, ε for IgE.
  • Two identical light (L) chains — approximately 25 kDa each. Two light-chain isotypes exist: kappa (κ) and lambda (λ). In humans, the normal κ:λ ratio is approximately 2:1.

Domain Structure

Each chain folds into globular domains of approximately 110 amino acids, stabilised by an intra-chain disulphide bond:

  • Variable domains (VH and VL) — located at the amino-terminal ends; together they form the antigen-binding site (paratope). Hypervariable regions (complementarity-determining regions, CDR1–3) within the variable domains confer antigen specificity.
  • Constant domains (CH1–3 or CH1–4, and CL) — located carboxy-terminal to the variable domains; determine isotype, mediate effector functions, and interact with Fc receptors and complement.

Hinge Region

In IgG, IgA, and IgD, a flexible hinge region between CH1 and CH2 allows the two Fab arms to adopt variable angles, enabling bivalent binding to antigens of differing spacing. IgM and IgE lack a classical hinge region; instead, an additional constant domain (CH4) provides structural rigidity.

Fab and Fc Fragments

Papain digestion cleaves IgG above the hinge to yield:

  • Fab (fragment antigen-binding) — one VH–CH1 paired with one VL–CL; monovalent antigen binding.
  • Fc (fragment crystallisable) — the paired CH2 and CH3 (or CH3–4 in IgM/IgE) domains; mediates complement activation, Fc-receptor binding, neonatal Fc receptor (FcRn) binding, and determines half-life.
💡
Pepsin digestion cleaves below the hinge, leaving a bivalent F(ab')2 fragment that retains antigen-binding capacity but lacks the Fc region and therefore cannot activate complement or bind Fc receptors. This principle underlies therapeutic antibody fragments such as ranibizumab.

Immunoglobulin Classes

Property IgG IgA IgM IgD IgE
Serum concentration (adult) 7.0–16.0 g/L (≈75 % of total Ig) 0.8–4.5 g/L (≈15 %) 0.5–2.0 g/L (≈8 %) Trace (<0.03 g/L) Trace (<0.00005 g/L)
Heavy chain γ (gamma) α (alpha) μ (mu) δ (delta) ε (epsilon)
Structure Monomer Dimer (+ J chain + SC) Pentamer (+ J chain) Monomer Monomer
Half-life (days) 21–28 5–6 (serum) 5 2.8 2
Placental transfer Yes (via FcRn) No No No No
Complement activation (classical) Yes (IgG1, IgG3 > IgG2) No Yes (very potent) No No
Primary role Secondary/memory response; opsonisation; ADCC; neonatal passive immunity Mucosal defence (secretory IgA) Primary response; natural antibodies; BCR B-cell receptor; B-cell maturation Type I hypersensitivity; anti-helminthic defence

IgG Subclasses

IgG is divided into four subclasses with distinct effector profiles:

Subclass % of IgG Half-life (days) Complement FcγR binding Clinical significance
IgG1 60–70 % 21 Strong Strong (FcγRI, FcγRII, FcγRIII) Most abundant; key opsonin; deficiency causes recurrent sinopulmonary infections
IgG2 20–30 % 21 Moderate Weak Anti-polysaccharide responses (pneumococcus, Haemophilus); deficiency → encapsulated organism infections
IgG3 5–8 % 7 Very strong Very strong Short half-life due to hinge-region polymorphism; potent pro-inflammatory subclass
IgG4 3–4 % 21 None Weak Anti-inflammatory; undergoes Fab-arm exchange; elevated in IgG4-related disease

IgA Subclasses

IgA1 predominates in serum, whereas IgA2 is more abundant at mucosal surfaces (resistant to bacterial proteases). Secretory IgA (sIgA) is a dimer of IgA monomers linked by a J chain and bound to the secretory component (SC) derived from the polymeric immunoglobulin receptor (pIgR). sIgA is the dominant immunoglobulin in breast milk, saliva, tears, and gut luminal secretions.

⚠️
IgA deficiency and IVIg safety: Selective IgA deficiency (serum IgA < 0.07 g/L) affects approximately 1 in 300–700 Australians of European descent. Patients with IgA deficiency who develop anti-IgA antibodies are at risk of anaphylaxis when receiving IVIg products containing trace IgA. Use IgA-depleted products (e.g., Privigen < 1 µg/mL, Gammagard Liquid < 1 µg/mL) and administer under close monitoring.

Effector Functions

1. Neutralisation

Antibodies bind to pathogen surface molecules (e.g., viral spike proteins, bacterial toxins) and physically block attachment to host-cell receptors. This is the primary mechanism of protection for most viral vaccines, including the influenza and SARS-CoV-2 vaccines used in Australia's National Immunisation Programme (NIP).

2. Opsonisation and Phagocytosis

IgG coating of pathogens (opsonisation) facilitates recognition by Fcγ receptors (FcγRI/CD64, FcγRII/CD32, FcγRIII/CD16) on macrophages and neutrophils, enhancing phagocytosis. IgG1 and IgG3 are the most efficient opsonins due to their strong FcγR binding and long hinge regions.

3. Complement Activation (Classical Pathway)

IgM (pentameric) and IgG (IgG1, IgG3) activate the classical complement pathway by binding C1q to their Fc regions. This leads to:

  • C3b deposition → enhanced opsonisation
  • C3a and C5a release → anaphylatoxin-mediated inflammation and chemotaxis
  • C5b–9 membrane attack complex (MAC) formation → direct lysis of susceptible organisms (especially Neisseria species)

4. Antibody-Dependent Cellular Cytotoxicity (ADCC)

IgG bound to target-cell surfaces engages FcγRIII (CD16) on natural killer (NK) cells, triggering release of perforin and granzymes. ADCC is a critical mechanism of tumour-cell killing in cancer immunotherapy (e.g., rituximab-mediated depletion of CD20⁺ B cells in lymphoma).

5. Mast-Cell and Basophil Degranulation

IgE binds with very high affinity (Kd ≈ 10⁻¹⁰ M) to FcεRI on mast cells and basophils. Cross-linking of surface IgE by multivalent allergens triggers degranulation, releasing histamine, leukotrienes, and prostaglandins — the basis of type I hypersensitivity (allergic rhinitis, asthma, anaphylaxis).

6. Neonatal Fc Receptor (FcRn) Recycling

FcRn in vascular endothelium and syncytiotrophoblast binds the Fc region of IgG at acidic pH (endosome), rescuing it from lysosomal degradation and recycling it to the cell surface. This mechanism:

  • Extends the IgG half-life to 21–28 days (longest of all immunoglobulin classes).
  • Mediates active transplacental transfer of maternal IgG to the foetus, particularly in the third trimester, providing passive neonatal immunity for the first 3–6 months of life.
✅
Clinical pearl: The FcRn recycling mechanism is exploited therapeutically by efgartigimod (anti-FcRn antibody), approved in Australia by the TGA (2023) for generalised myasthenia gravis. By blocking FcRn, efgartigimod accelerates IgG catabolism, reducing pathogenic autoantibody levels.

Clinical Applications

A. Immunoglobulin Replacement Therapy

Indicated for patients with primary or secondary immunodeficiency characterised by impaired antibody production.

Replacement
Primary Immunodeficiency
X-linked agammaglobulinaemia, common variable immunodeficiency (CVID), specific antibody deficiency, combined immunodeficiency.
Dose: IVIg 0.4–0.6 g/kg every 3–4 weeks OR SCIg 0.1–0.2 g/kg weekly
Replacement
Secondary Immunodeficiency
Chronic lymphocytic leukaemia (CLL), multiple myeloma, post-haematopoietic stem-cell transplant, protein-losing enteropathy, nephrotic syndrome.
Dose: IVIg 0.4 g/kg every 3–4 weeks; target trough IgG ≥ 5 g/L (or ≥ pre-infection nadir + 2 g/L)

B. Immunomodulatory Applications

High-dose immunoglobulin exerts immunomodulatory effects via Fc-receptor saturation, anti-idiotypic antibody-mediated neutralisation of autoantibodies, cytokine modulation, and complement scavenging.

💉
Immune Thrombocytopenia (ITP)
Acute ITP in adults and children
Adult dose IVIg 1 g/kg (max 40 g) on day 1, may repeat day 2; OR 0.4 g/kg/day for 2–5 days
Paediatric dose 0.8–1 g/kg as single infusion; or 0.4 g/kg/day × 5 days
PBS status ✔ PBS General Benefit
💊
Kawasaki Disease
Standard treatment with aspirin
Paediatric dose IVIg 2 g/kg as single infusion over 10–12 hours, within 10 days of fever onset
Efficacy Reduces coronary-artery aneurysm rate from ~25 % to ~4 %
PBS status ✔ PBS General Benefit
💊
Guillain-Barré Syndrome (GBS)
First-line immunomodulation
Adult dose IVIg 0.4 g/kg/day for 5 days (total 2 g/kg)
Efficacy Equivalent to plasma exchange; faster recovery when started within 2 weeks of onset
PBS status ✔ PBS General Benefit
💊
CIDP
Chronic inflammatory demyelinating polyneuropathy
Induction IVIg 2 g/kg over 2–5 days
Maintenance IVIg 1 g/kg every 3–4 weeks OR SCIg 0.2–0.4 g/kg weekly
PBS status ✔ PBS General Benefit

C. IVIg Products Available in Australia

Product Manufacturer Concentration IgA content Route
Intragam P CSL Behring 6 % (60 mg/mL) ≤ 20 µg/mL IV
Privigen CSL Behring 10 % (100 mg/mL) ≤ 25 µg/mL IV
Flebogamma 10 % DIF Grifols 10 % (100 mg/mL) ≤ 50 µg/mL IV
Kiovig Takeda / Baxalta 10 % (100 mg/mL) ≤ 10 µg/mL IV
Hizentra CSL Behring 20 % (200 mg/mL) ≤ 50 µg/mL SC
Cuvitru Takeda / Baxalta 20 % (200 mg/mL) ≤ 10 µg/mL SC
Subcuvia CSL Behring 16 % (160 mg/mL) ≤ 320 µg/mL SC

D. Adverse Effects & Safety Monitoring

⚠️
Pre-infusion checklist: (1) Verify patient IgA level — if < 0.07 g/L, consider IgA-depleted product. (2) Assess thromboembolic risk factors (age > 65, immobility, oestrogen use, prior VTE, hyperviscosity). (3) Ensure adequate hydration. (4) Administer paracetamol ± antihistamine as premedication if history of infusion reactions. (5) Start at recommended initial rate and titrate per product guidelines.
Adverse Effect Frequency Management
Headache, myalgia, chills, flushing Common (5–15 %) Slow rate; paracetamol; IV fluids
Aseptic meningitis Uncommon (< 5 %) Stop infusion; LP if diagnostic uncertainty; supportive care; consider alternative product
Anaphylaxis (IgA-deficient patients) Rare (< 1 %) IM adrenaline 0.01 mg/kg (max 0.5 mg adults); switch to IgA-depleted product
Thromboembolism (DVT, PE, stroke, MI) Rare (< 1 %) Risk mitigation: adequate hydration, slow infusion rate, avoid concurrent high-dose IV corticosteroids
Haemolytic anaemia (anti-A/anti-B) Uncommon Monitor FBC and haptoglobin post-infusion; ABO-compatible products where available
Renal impairment (sucrose-containing products) Rare Avoid sucrose-stabilised formulations in CKD; monitor eGFR; use osmotic-nephrosis-safe products (e.g., Intragam P, Privigen)
Transfusion-transmission infection Extremely rare Australian products undergo multiple virucidal steps (pasteurisation, low-pH incubation, solvent/detergent, nanofiltration)

E. Therapeutic Monoclonal Antibodies (Selected)

Recombinant monoclonal antibodies are engineered immunoglobulin-derived biologics. Selected examples relevant to Australian practice include:

Monoclonal antibody Target Indication PBS status
Rituximab (MabThera®) CD20 B-cell lymphoma, CLL, RA, ANCA vasculitis ✔ PBS General Benefit
Trastuzumab (Herceptin®) HER2 HER2⁺ breast cancer ✔ PBS General Benefit
Infliximab (Remicade®) TNF-α Crohn disease, ulcerative colitis, RA, psoriasis ✔ PBS Restricted Benefit
Omalizumab (Xolair®) IgE (Cε3 domain) Severe allergic asthma, chronic spontaneous urticaria ✔ PBS Restricted Benefit
Dupilumab (Dupixent®) IL-4Rα Moderate–severe atopic dermatitis, asthma, CRSwNP ✔ PBS Restricted Benefit
Nivolumab (Opdivo®) PD-1 Melanoma, NSCLC, RCC, others ✔ PBS Restricted Benefit

F. Diagnostic Immunoglobulin Assessment

Immunoglobulin quantification is performed by nephelometry or turbidimetry (RCPA-accredited laboratories). Key indications for testing include recurrent infections, suspected immunodeficiency, paraproteinaemia, and autoimmune disease monitoring.

MBS 69440
Serum immunoglobulins (IgG, IgA, IgM)
Quantitative nephelometry. Available at all public and private pathology laboratories in Australia. Medicare-rebatable.
MBS 69446
IgG subclasses (IgG1–4)
Indicated when total IgG is normal but recurrent encapsulated organism infections are present. Specialist-initiated.
MBS 69440
Serum IgE (total and specific)
Total IgE quantification; specific IgE panels (e.g., Phadia ImmunoCAP) for allergen identification. Medicare-rebatable.
Specialist
Serum free light chains (κ and λ) and ratio
Essential for paraprotein assessment and AL amyloidosis screening. MBS 69495. Specialist-initiated.
Specialist
Serum protein electrophoresis (SPEP) and immunofixation
Detection and characterisation of monoclonal paraproteins (M band). MBS 69460/69463.
MBS 69440
Anti-IgA antibodies
Pre-IVIg assessment in patients with known or suspected IgA deficiency. Not routinely performed; request via specialist immunology laboratory.

G. Vaccination Considerations

Patients receiving immunoglobulin replacement therapy have impaired vaccine antibody responses during and for several months after infusion. Key Australian recommendations include:

  • Live vaccines (MMR, varicella, yellow fever) — contraindicated during immunoglobulin therapy and for ≥ 8 months after the last dose (longer interval for high-dose immunomodulatory IVIg).
  • Inactivated vaccines — can be administered but antibody responses may be blunted; consider checking post-vaccination titres (e.g., anti-pneumococcal IgG) 4–6 weeks after vaccination.
  • Influenza vaccine — recommended annually per NIP schedule regardless of immunoglobulin therapy.
  • COVID-19 vaccine — recommended per ATAGI guidance; immunoglobulin therapy does not alter the vaccine schedule.

Special Populations

🤰 Pregnancy
IgG crosses the placenta via FcRn (active transport from ~13 weeks, accelerating in third trimester).
IVIg is Category B2 in Australia. Safe for replacement therapy and immunomodulation (e.g., ITP) during pregnancy. Monitor maternal IgG trough levels as volume of distribution increases.
IgA does NOT cross the placenta — neonatal IgA levels are negligible at birth.
IgA is primarily obtained postnatally via breast milk (sIgA). Support breastfeeding in immunodeficient mothers.
Anti-D immunoglobulin (Rhophylac®)
PBS General Benefit. Administered to RhD-negative mothers at 28 weeks and within 72 hours of delivery of an RhD-positive infant to prevent haemolytic disease of the newborn.
👶 Paediatrics
Passive immunity
Maternal IgG transferred across the placenta provides protection for the first 3–6 months of life. IgG levels fall to a nadir at 3–6 months (physiological hypogammaglobulinaemia of infancy) before endogenous production increases.
IVIg dosing for immunodeficiency
400–600 mg/kg every 3–4 weeks. SCIg (Hizentra®) can be used in children ≥ 2 years for home-based therapy. Weight-based dosing adjustments required as the child grows.
Kawasaki disease
Single dose of IVIg 2 g/kg over 10–12 hours with aspirin (30–50 mg/kg/day in acute phase, then 3–5 mg/kg/day). Non-responders (fever at 36–48 hours): repeat IVIg 2 g/kg or consider corticosteroids.
👴 Elderly
Thromboembolic risk
Patients aged ≥ 65 years have increased risk of IVIg-associated thromboembolism. Ensure adequate pre-infusion hydration (≥ 500 mL oral/IV fluids), use slow infusion rates, and consider prophylactic anticoagulation in high-risk patients.
Renal impairment
Age-related decline in eGFR increases risk of osmotic nephrosis with sucrose-containing IVIg. Avoid Sandoglobulin® (sucrose-stabilised). Monitor renal function before and after each infusion.
🫘 Renal Impairment
Product selection
Use sucrose-free products (Intragam P, Privigen, Kiovig). Avoid sucrose-containing IVIg (risk of osmotic nephrosis). Monitor serum creatinine and urine output during infusion.
Dose adjustment
No dose adjustment is required for immunoglobulin replacement in renal impairment. However, reduce infusion rate and ensure adequate hydration.
🫁 Hepatic Impairment
No dose adjustment required
IgG catabolism occurs via the reticuloendothelial system and is not significantly affected by hepatic impairment. However, patients with liver disease may have coagulopathy and are at increased thromboembolic risk; use with caution and slow infusion rates.
🛡️ Immunocompromised
Post-HSCT
IVIg replacement (0.4–0.5 g/kg every 1–4 weeks) is indicated for allogeneic HSCT recipients with IgG < 4 g/L or recurrent infections until immune reconstitution (typically 6–12 months post-transplant).
CLL / Myeloma
IVIg replacement reduces the incidence of serious bacterial infections. NIGP-approved indication. Target trough IgG ≥ 5 g/L.
Rituximab-associated hypogammaglobulinaemia
Recurrent CD20-depleting therapy may cause sustained hypogammaglobulinaemia. Monitor IgG levels; consider IVIg replacement if IgG < 4 g/L with recurrent sinopulmonary infections.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Infection burden
Aboriginal and Torres Strait Islander peoples experience a significantly higher burden of infectious diseases, including invasive pneumococcal disease, rheumatic heart disease, and chronic suppurative lung disease, which may necessitate immunoglobulin therapy or benefit from improved passive immunity strategies.
Geographic access
Many Indigenous Australians in remote and very remote communities face significant barriers to accessing specialist immunology services and regular IVIg infusions. SCIg (self-administered subcutaneous immunoglobulin) offers a practical alternative for eligible patients, enabling home-based therapy with appropriate training and remote monitoring via telehealth.
Plasma donation
Lifeblood collects plasma from a limited number of centres in regional Australia. Expansion of plasma-donation access and culturally safe donation centres in areas with large Indigenous populations would support equitable plasma-product supply.
Paediatric immunodeficiency
Indigenous children have higher rates of bronchiectasis and chronic suppurative otitis media, which may be associated with undiagnosed primary or secondary antibody deficiencies. Low thresholds for serum immunoglobulin and specific antibody testing are recommended in children with recurrent severe infections (≥ 2 hospitalisations per year for pneumonia, or ≥ 4 ear infections per year).
Cultural safety
Immunoglobulin therapy (especially IVIg) requires intravenous access, often necessitating travel to regional hospitals. Community-controlled health services should be engaged in care planning. Use of Aboriginal Health Workers and Torres Strait Islander Health Practitioners as infusion-support staff can improve patient comfort and adherence.
Rheumatic heart disease
RHD disproportionately affects Aboriginal and Torres Strait Islander peoples, particularly in northern Australia. While penicillin prophylaxis is the cornerstone of RHD management, immunoglobulin-mediated immune responses to Group A Streptococcus are central to disease pathogenesis. Understanding the immunoglobulin response informs vaccine-development efforts (no GAS vaccine is currently available).

📚 References

  1. 1. Australian Government Department of Health and Aged Care. National Immunoglobulin Governance Programme: Clinical Criteria for Immunoglobulin Use in Australia. 3rd edn. Canberra: Commonwealth of Australia; 2015 (updated 2022).
  2. 2. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health and Aged Care, Canberra; 2022. Available at: immunisationhandbook.health.gov.au.
  3. 3. National Blood Authority Australia. National Blood Agreement. Canberra: NBA; 2003 (revised 2021).
  4. 4. Royal College of Pathologists of Australasia (RCPA). Immunoglobulin quantification and electrophoresis: RCPA Manual. Sydney: RCPA; 2023.
  5. 5. Australasian Society of Clinical Immunology and Allergy (ASCIA). Primary Immunodeficiency (PID) Position Statement. Sydney: ASCIA; 2023.
  6. 6. Ballow M, Cunningham-Rundles C. Intravenous immunoglobulin: clinical applications and safety. J Allergy Clin Immunol. 2023;151(3):612–624.
  7. 7. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30.
  8. 8. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–S46.
  9. 9. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework 2023 Summary Report. Canberra: AIHW; 2023.
  10. 10. Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41–S52.
  11. 11. Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des. 2011;17(29):3166–3175.
  12. 12. Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. Immunotherapy. 2019;11(11):967–975.
  13. 13. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015–2025.
  14. 14. Emergency Care Institute, NSW. Kawasaki Disease: Clinical Practice Guideline. Sydney: ACI; 2022.
  15. 15. National Blood Authority Australia. Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia. Canberra: NBA; 2012.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).